history of glp 1 agonists Another milestone in the evolution GLP-1-based diabetes therapies Oral Small-Molecule GLP-1 Receptor Agonists:

Description

doi: 10.1080/14656566.2020.1748599 168 KadouhHChedidVHalawiHBurtonDDClarkMMKhemaniDet al

Pooled mean follow-up on-treatment for semaglutide users was 193 days (median 157 days, interquartile range (IQR) 85 to 331 days) and for sitagliptin users 195 days (median 160 days, IQR 95 to 322 days)

Delivering a peptide drug orally is challenging because the GI tract degrades proteins

GLP-1 RAs, including semaglutide, liraglutide and dual GIP/GLP-1 RAs, such as tirzepatide, are used in the treatment of diabetes mellitus and weight loss

9 , 10 Many patients struggle to maintain the necessary behavioral changes long term, leading to modest results which are often inadequate in addressing the complex physiological, genetic, and environmental factors underlying obesity